Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Journal of Virology
Olivia GoethalsKurt Hertogs

Abstract

Integration of viral DNA into the host chromosome is an essential step in the life cycle of retroviruses and is facilitated by the viral integrase enzyme. The first generation of integrase inhibitors recently approved or currently in late-stage clinical trials shows great promise for the treatment of human immunodeficiency virus (HIV) infection, but virus is expected to develop resistance to these drugs. Therefore, we used a novel resistance selection protocol to follow the emergence of resistant HIV in the presence of the integrase inhibitor elvitegravir (GS-9137). We find the primary resistance-conferring mutations to be Q148R, E92Q, and T66I and demonstrate that they confer a reduction in susceptibility not only to elvitegravir but also to raltegravir (MK-0518) and other integrase inhibitors. The locations of the mutations are highlighted in the catalytic sites of integrase, and we correlate the mutations with expected drug-protein contacts. In addition, mutations that do not confer reduced susceptibility when present alone (H114Y, L74M, R20K, A128T, E138K, and S230R) are also discussed in relation to their position in the catalytic core domain and their proximity to known structural features of integrase. These data broaden...Continue Reading

References

Feb 26, 1998·Antiviral Research·E Asante-Appiah, A M Skalka
Jun 29, 1999·Advances in Virus Research·D Esposito, R Craigie
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y GoldgurD R Davies
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·Ryan ReinkeW Edward Robinson
Mar 5, 2004·The New England Journal of Medicine·François Clavel, Allan J Hance
Jul 28, 2004·Proceedings of the National Academy of Sciences of the United States of America·Daria J HazudaSteven D Young
Aug 24, 2004·Current Drug Metabolism·M WitvrouwZ Debyser
Feb 25, 2005·Nature Reviews. Drug Discovery·Yves PommierChristophe Marchand
Mar 3, 2006·Journal of Medicinal Chemistry·Motohide SatoHisashi Shinkai
Aug 29, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Edwin DeJesusUNKNOWN 183-0101 Study Team
Feb 3, 2007·Current Pharmaceutical Design·Jinxia DengNouri Neamati
Apr 17, 2007·Lancet·Pedro Cahn, Omar Sued
Nov 6, 2007·Medicinal Research Reviews·Raveendra DayamNouri Neamati
Dec 22, 2007·Expert Opinion on Investigational Drugs·Mary Anker, Roberto B Corales
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin

❮ Previous
Next ❯

Citations

Nov 28, 2012·Current Infectious Disease Reports·Peter K QuashieMark A Wainberg
Feb 16, 2013·Drugs·Sharon L Karmon, Martin Markowitz
Oct 5, 2013·Bioorganic & Medicinal Chemistry Letters·Horrick SharmaJohn K Buolamwini
Apr 7, 2010·The Journal of Biological Chemistry·Nicholas C FitzkeeAd Bax
Jul 22, 2009·AIDS Research and Human Retroviruses·Li XuErasmus Smit
Apr 5, 2011·The Journal of Infectious Diseases·Jose-Luis BlancoRobert W Shafer
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·Patricia A Cane
Aug 13, 2011·AIDS·Rithun MukherjeeFrederic D Bushman
Oct 6, 2011·AIDS·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Jul 17, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Zixin Hu, Daniel R Kuritzkes
Aug 11, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark R UnderwoodTamio Fujiwara
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Eric J Arts, Daria J Hazuda
Oct 30, 2013·Antimicrobial Agents and Chemotherapy·Caroline O BushRudolf K F Beran
Dec 25, 2012·BMC Infectious Diseases·Miłosz ParczewskiAnna Boroń-Kaczmarska
Apr 14, 2012·BMC Medicine·Peter K QuashieMark A Wainberg
Apr 7, 2010·European Journal of Medical Research·Francois Clavel
Jan 24, 2013·PloS One·Peter MessiaenLinos Vandekerckhove
Feb 22, 2012·HIV/AIDS : Research and Palliative Care·Janice Soo Fern LeeNathan Ford
Feb 16, 2013·HIV/AIDS : Research and Palliative Care·Alessandra FantauzziIvano Mezzaroma
Jun 23, 2011·Infection and Drug Resistance·Jean L MbisaPatricia A Cane
Oct 30, 2010·Proceedings of the National Academy of Sciences of the United States of America·Stephen HarePeter Cherepanov
Jan 17, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christina GagliardoNatalie Neu
Apr 9, 2014·The Journal of Antimicrobial Chemotherapy·Isabelle MaletAnne-Geneviève Marcelin
Dec 3, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wan-Gang Gu
Oct 25, 2014·Viruses·Pinar Iyidogan, Karen S Anderson
Aug 17, 2010·Expert Opinion on Investigational Drugs·Nicole Prada, Martin Markowitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.